Period | ASA dose | Cases | Controls | Model 1 | Model 2 |
---|---|---|---|---|---|
HR (95% CI) | HR (95% CI) | ||||
A | - Baseline (3 to 9 months after diagnosis) | ||||
(n = 1521) | (n = 3042) | ||||
0 | 1235 (81.2) | 2481 (81.6) | 1.00 | 1.00 | |
<1 daily dose | 78 (5.1) | 146 (4.8) | 1.08 (0.81; 1.44) | 1.13 (0.84; 1.52) | |
≥ 1 daily dose | 208 (13.7) | 415 (13.6) | 1.01 (0.84; 1.23) | 0.97 (0.79; 1.18) | |
B | - 12 to 6 months before end of follow-up | ||||
(n = 1211) | (n = 2422) | ||||
0 | 964 (79.6) | 1961 (81.0) | 1.00 | 1.00 | |
<1 daily dose | 72 (5.9) | 138 (5.7) | 1.08 (0.80; 1.46) | 1.05 (0.77; 1.44) | |
≥ 1 daily dose | 175 (14.5) | 323 (13.3) | 1.12 (0.90; 1.38) | 1.02 (0.81; 1.28) | |
C | - 9 to 3 months before end of follow-up | ||||
(n = 1380) | (n = 2760) | ||||
0 | 1102 (79.9) | 2216 (80.3) | 1.00 | 1.00 | |
<1 daily dose | 81 (5.9) | 152 (5.5) | 1.07 (0.81; 1.42) | 1.00 (0.74; 1.34) | |
≥ 1 daily dose | 197 (14.3) | 392 (14.2) | 1.01 (0.83; 1.24) | 0.93 (0.75; 1.15) | |
D | - 6 to 0 months before end of follow-up | ||||
(n = 1521) | (n = 3042) | ||||
0 | 1220 (80.2) | 2420 (79.6) | 1.00 | 1.00 | |
<1 daily dose | 120 (7.9) | 159 (5.2) | 1.49 (1.16; 1.92) | 1.43 (1.09; 1.87) | |
≥ 1 daily dose | 181 (11.9) | 463 (15.2) | 0.77 (0.63; 0.93) | 0.69 (0.56; 0.86) |